Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.
Julia Fehniger, MD
Advertisement
Articles by Julia Fehniger, MD
Advertisement
Latest Updated Articles
Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic CancersPublished: February 9th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5